Evaluation of Leptin Levels in Major beta-Thalassemic Patients

Choobineh H,1 Dehghani SJ,1 Alizadeh Sh,2 Ghobadi Dana V,3 Saiepour N,4 Meshkani R,5 Einollahi N1

1Department of Medical Laboratory Sciences, Faculty of Para-Medicine, Tehran University of Medical Sciences
2Department of Hematology and Blood Banking, Faculty of Para-Medicine, Tehran University of Medical Sciences
3Department of Pediatrics, Faculty of Medicine, Tehran University of Medical Sciences
4Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences
5Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences

Corresponding author: Hamid Choobineh
Department of Medical Laboratory Sciences, Faculty of Para-Medicine, Medical Sciences University of Tehran, Poorsina Street, Ghods Street, Enghelab Avenue, Tehran, Iran
Mail code: 1417744181
Phone: +98-21-88964009
E-mail: haematology83@gmail.com

Abstract

Introduction: Leptin is an adipocyte-derived hormone. Exogenous leptin allows the recovery of the reproductive function. In humans, leptin correlates positively with the body mass index (BMI). The aim of this study was to investigate the association of leptin with the toxic effects of iron overload.

Methods: 219 Major Beta thalassemic patients (119 men, 100 women) and 137 non thalassemic individuals (86 men, 51 women) were investigated on the basis of a case control study. Data was gathered from six hospitals related to Tehran University during a seven month period (July 2006–January 2007). Blood samples of all major beta thalassemic patients who were admitted to these hospitals for recurrent blood transfusion were collected. Non thalassemic individuals were selected from outpatients who without significant medical problems, had come to these hospitals and had extra blood sample. The similarities of the two groups in age, gender and BMI also were considered.

Results: The serum leptin level median was 5.00 (interquartile range: 6.50) for major beta thalassemic patients and 6.10 (interquartile range: 7.00) for healthy individuals. Serum leptin level was significantly lower in thalassemic patients (P value <0.001). Major beta thalassemic men had significantly lower leptin level (median, interquartile range: 2.90, 3.60) than major beta thalassemic women (median, interquartile range: 6.45, 16.02; P value <0.001).

Conclusions: This study confirmed that the adipocytes of major beta thalassemic patients are unable to maintain adequate leptin production. These results suggest that adipose tissue dysfunction can be considered one of the endocrinopathies affecting major beta thalassemic patients.

Key words: Major Beta Thalassemia, Leptin, BMI

Received: 28, Aug., 2010
Accepted: 26, Sep., 2010

Introduction

Major Beta thalassemia, which is a blood disorder, results from a reduction in the synthesis of hemoglobin β chain (Hgb), and leads to an increase of the α chain in erythroid precursors. The accumulation of α chain forms an abnormal α₄ molecule which is unstable and precipitates into the plasma membrane of red blood cells (RBCs). RBCs are lysed and lost in the reticuloendothelial system; thus, major β thalassemia is classified as a hemolytic anemia.(1,2) The severity of β thalassemia differs according to the level of β chain synthesis. Patients with major β thalassemia are dependent on recurrent blood transfusions for a long life. Blood transfusion not only causes transmission of infection diseases but also leads to premature death, as the result of an iron overload in various vital organs such as the liver and heart.(1,2) In addition to suffering from severe pain, thalassemic patients have shortened lives in comparison with healthy individuals.(1-3) Growth retardation and delay in puberty, short
stature, thinness and hypogonadism are the main problems of the thalassemic patients. The main causes of these abnormalities are not clearly understood. Hypophyseal dysfunction and decreasing gonadotropic hormones are considered as the causative factors. Relatively, the injection of gonadotropic hormones has relatively solved some of these problems.(3-6)

Leptin is a polypeptide hormone that was discovered in 1994. Leptin is a non-glycosylated protein with 146 amino acids which is positively correlated with serum lipid and the body mass index.(7-9) This hormone has diurnal variability with the peak level being at night. It appears that it is regulated by insulin.(10-11) Studies within different populations have shown that women have a higher level of leptin than men, indicating that sex hormones probably play a major role in regulating this hormone.(12-13) Leptin is the product of the obese gene (ob) that is mainly expressed in bone marrow (BM) and adipocytes. A decrease of leptin in knockout mice (ob/ob) leads to some phenotypic characteristics such as small gonads, thinness and infertility which all are reversible with hormone replacement. It also has been suggested that leptin affects hematopoietic stem cells and plays a role in erythropoiesis.(14-15)

Leptin and its receptor possess similarities to (IL)-6, IL-11, IL-12, the leukemia inhibitory factor (LIF), granulocyte-colony stimulating factor (G-CSF) and Oncostatin M (OSM).

The leptin receptor is a member of the hematopoietin receptor family, expressed in yolk sac, fetal liver, bone marrow, and hematopoetic stem cells. Leptin and erythropoietin can synergistically increase erythroid development. Knock out of leptin receptor results in impaired erythrocyte production.

Considering the abnormalities in thalassemic patients and the effects of leptin on erythropoiesis and sexual maturation, we aimed to investigate the possible relation between leptin and major beta thalassemia in the Iranian population.

**Methods**

The cases of 356 individuals were researched in this case control study. This consisted of 219 thalassemic patients (119 men, 100 women) and 137 non-thalassemic individuals (86 men, 51 women) who were investigated the basis of the case control study. Data was gathered from six hospitals related to Tehran University of Medical Sciences during a seven months period (July 2006– January 2007). Age, sex, height, weight and birth date were recorded. Blood samples of all thalassemic patients who had been admitted to these hospitals for recurrent blood transfusion were collected. Non-thalassemic individuals were selected from outpatients who without significant medical problems, had come to these hospitals and had given extra blood samples. The similarity of the two groups in age, gender and BMI was also were considered.

Blood samples (5ml) were collected without any anticoagulant agent. The serum was separated and kept at -20° until laboratory tests. Characteristics of all subjects (like age and weight) were recorded. BMI was calculated by the kg/m² formula. Excluding criteria were a lack of extra blood samples sufficient for the tests or samples were lost while performing the tests. Written informed consent was obtained from all participants before enrollment in the study.

Leptin level in the serum was measured by Elisa kit (Diagnostic Biochem Canada Inc Cat. No: CAN-L-4260), according to kit prescription. The sensitivity of the kit was 0.5 ng/ml.

The Mann-Whitney test was used for comparisons, and the Spearman correlation coefficient was used as a test of correlation. Analyses were performed using SPSS software.

**Results**

A total of 356 people, consisting of 219 major beta thalassemic patients and 137 non-thalassemic individuals were subjects of the research as the basis of case control study.

Of the beta thalassemic patients, 119 (54.3%) were males and 100 (45.7%) were females. The age median was 15.3 ±7.1 in beta thalassemic patients and 15.5±4.2 in healthy individuals. Also the weight and height mean was 36.5±13.6 and 129±34.5 in beta thalassemic patients and 39.5±11.3 &132±28.8 in healthy people respectively.

According to the filled questionnaires 2.3% of patients had been using antiviral drugs. The interval between transfusions was 3 weeks in 6% of the patients and 4 weeks in the reminder of them. All of the patients were regularly repeated transfused patients. The characteristics of the study group aged 2–29 years of age are shown in Table 1.

The Leptin level median was 5.00 ng/ml (inter-quartile range: 6.50) for major beta thalassemia patients and 6.10 ng/ml (inter-quartile range: 7.00) for healthy individuals. Serum leptin level was significantly lower in major beta thalassemia patients (P value <0.001). major beta thalassemic
Table 1: General characteristics of the study group

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (Male/Female)</td>
<td>119/100</td>
<td>86/51</td>
</tr>
<tr>
<td>Age (mean ± SD)*</td>
<td>15.3±7.1</td>
<td>15.5±4.2</td>
</tr>
<tr>
<td>Weight (mean ± SD)†</td>
<td>36.5±13.6</td>
<td>39.5±11.3</td>
</tr>
<tr>
<td>Height (mean ± SD)‡</td>
<td>129±34.5</td>
<td>132±28.8</td>
</tr>
</tbody>
</table>

* Year  
† Kilogram  
‡ Centimeter

men had significantly lower leptin level (median, inter quartile range: 2.90, 3.60) than major beta thalassemic women (median, inter quartile range: 6.45, 16.02; P value <0.001). Leptin level and BMI had no correlation in major beta thalassemia patients (P-value=0.67). However, leptin level and age were positively correlated among major beta thalassemia patients (Spearman correlation coefficient= 0.234, P-values= 0.002). (Fig. 1)

Discussion
This study showed that leptin level in major beta thalassemic patients was lower than the healthy subjects. This finding is in accordance with previous studies.(5-6, 16)

![Beta thalassemic patients and Healthy individuals](image)

![Beta thalassemic men and women](image)

Fig 1: Leptin levels in healthy individual and Major Beta thalassemic patients: In all bars gray bar shows median and dark bar shows inter quartile range, (a) Leptin level's median was 5.00 ng/ml (inter quartile range: 6.50) for Major Beta thalassemic patients and 6.10 ng/ml (inter quartile range: 7.00) for healthy individuals. Serum leptin level was significantly lower in Major Beta thalassemic patients (P value <0.001). (b) Major Beta thalassemic men had significantly lower leptin level (median, inter quartile range: 2.90, 3.60) than Major Beta thalassemic women (median, inter quartile range: 6.45, 16.02), (P value <0.001).

The most probable reason for such difference is the toxic effects of iron on cell membranes and proteins in the major beta thalassemic patients, since free iron causes peroxidative damage in lipid membrane and proteins with the generation of free OH radicals. Thus, in an iron overload (such as in major beta thalassemia) following the destructions of adipocyte, leptin level is decreased. Furthermore, the replacement of red BM with yellow BM which contains adipocytes (which is present in all hemolytic anemia according to the severity of the disease), can be the cause of this decrease.(2, 6, 15)

Although a positive and significant correlation between leptin and BMI has been widely observed by in other studies,(7-9, 17, 18) we did not find any correlation between the leptin and BMI in major beta thalassemic patients. This is in agreement with the result of some other studies.(5-6, 16) This can be attributed to a toxicity of iron overload in bone marrow and suggests a less active role of body fat mass in the regulation of circulating leptin in these patients. Animal studies have shown that iron overload and its deposition in subcutaneous layers significantly inhibits adipocyte function.(2, 15, 19)

In this study, a significant difference was found between the leptin levels of men and women in major beta thalassemic patients, which has been confirmed by other studies.(5-6, 19) The cause of higher leptin level in major beta thalassemic women compared to major beta thalassemic men is considered to be related to more adipose tissue in women and also to a difference in sex hormones than is related to a diminished iron overload in women. Similar to previous studies, we also found a significant positive correlation between age and the leptin level found in major beta thalassemic patient.(17-18) Perhaps this is related to an increase of adipose tissue with the age.

In a study by Guidance, et al, in Italy, mean values of leptin in patients and healthy subjects were 2.69 and 6.37, respectively.(5) In another study performed by Chaliouf, et al, these values were 3.21 and 8.62. In the present study, due to skewed data distribution, mean values were not used for analysis. But, it seems that the mean values of leptin level of major beta thalassemic and non-thalassemic individuals in our study are higher than in the previous studies. This discrepancy in leptin levels can be attributed to differences in sample size, dissimilarity of nutrition and locality and different antibody used to measure leptin. But, the most probable cause of such differences is due to the effect of leptin on hematopoiesis.(10-11) Since major beta thalassemia is not a monotonous disease,
the severity of anemia differs according to decreasing β chain synthesis, thus leptin level differ with different levels of anemia severity. In order to clarify this theory, a patient should be selected with known severity of anemia.

In conclusion, our results from a sample of the Iranian population support the idea that major beta thalassemia is associated with lower level of leptin. In addition, confirming similar studies, this study demonstrated that women have higher levels of leptin than men. Considering this issue further, studies using synthetic hormones in animal and humans can potentially help to decrease the problems of major beta thalassemic patients.

Acknowledgements: We greatly appreciate the assistance provided by Saeed Mohammad-zadeh from department of Agricultural Extension and Education, the University of Tehran. We also thank all volunteers for their participation in the study. This research was supported by Tehran University of Medical Sciences and health Services grant (No 2740).

References